title: Is rituximab-induced late-onset neutropenia a good prognostic indicator in lymphoproliferatve disorders?
authors.forename: Ian
authors.initials: I
authors.lastname: Hincks
authors.forename: Barrie E
authors.initials: BE
authors.lastname: Woodcock
authors.forename: Jecko
authors.initials: J
authors.lastname: Thachil
mesh_terms: D058846:Antibodies, Monoclonal, Murine-Derived / Q000009:adverse effects*; D000970:Antineoplastic Agents / Q000009:adverse effects*; D005260:Female; D006801:Humans; D008224:Lymphoma, Follicular / Q000188:drug therapy*; D008232:Lymphoproliferative Disorders / Q000188:drug therapy; D008875:Middle Aged; D009503:Neutropenia / Q000139:chemically induced*; D011379:Prognosis; D012074:Remission Induction; D000069283:Rituximab
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D000069283:Rituximab